Bpifrance

Bpifrance is a financial institution dedicated to supporting companies throughout their development stages, particularly those preparing for stock market listing and seeking credit equity. The organization provides a range of financial solutions, including financing, innovation assistance, and capital investment. By integrating various entities such as OSEO and CDC Entreprises, Bpifrance aims to deliver tailored financial support that addresses the specific needs of businesses. The institution is committed to fostering innovation and helping companies transition toward sustainable growth, ensuring they are well-equipped to face future challenges.

Laurent Arthaud

Managing Director

Marion Aubry

Investment Director

Emmanuel Audouard

Director of Transverse Venture Capital Investments Division

Benoit Barteau Ph.D

Investment Director

Nicolas Berdou

Investment Director, Defense Expert

Clarisse Blandin

Investment Director

Edouard Combette

Investment Director

Charlotte Corbaz

Deputy Director of the Large Venture Fund and Deputy Managing Director

Nicolas Dardenne

Senior Investment Director, Normandy (Caen Rouen)

Arnaud Despoisse

Director of Occitanie Participations

Philippe Dutheil

Investment Director

Mailys Ferrere

Director of Large Venture Investments

Jean-Marie Fougeray

Senior Investment Director, Brittany

Paul-Francois Fournier

Executive Director, Innovation Department

Pierre Gillet

Investment Director

Vanessa Giraud

Managing Director

Gwenaël Hamon

Senior Investment Director

Laurent Higueret Ph.D

Senior Investment Director

Louis Janneau

Investment Director and Fund Manager

Magali Joessel

Director of Funds

So-Yeon Koo

Senior Investment Manager

Jérôme Langlade

Investment Director Aquitaine / Limousin / Poitou-Charentes

Eric Lefebvre

Director

Stephane Lefevre-Sauli

Senior Investment Director

Arnaud Legardeur

Investment Director

Chahra Louafi

Senior Investment Director

Elyssa Maufras du Châtellier

Investment Director

Quentin Mayolle

Senior Investment Officer

Serge Mesguich

Director of FIT

Laure Michel

Investment Director

Louis Molis

Investment Director

Jean-Francois Morin

Investment Director

Sébastien Moynot

Director

Adrien Muller

Investment Director

Adrien Néel

Investment Director

Axel Piriou

Director of Investments

Olivier Rameil

Senior Investment Director / VC seed

Vincent Roque

Director

Thibaut Roulon Ph.D

Investment Director

Gilles Schang

Deputy Director

Claire Waché

Senior Investment Officer

Past deals in Early Venture Stage

Chipiron

Series A in 2025
Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.

Versant

Grant in 2025
Tech solution to accelerate biodiversity restoration.

Faume

Series A in 2025
Faume provides a comprehensive white-label solution for businesses aiming to enter or dominate the circular economy market. Its platform enables brands to attract new customers, retain existing ones, and adopt sustainable practices by managing secondhand business operations.

Galam Robotics

Series A in 2025
Galam Robotics develops modular robotic solutions to optimize logistics and storage processes. The technology enhances productivity and compactness of stores and logistics hubs, transforming storage into constrained spaces to improve handling flows at high density and speed, enabling businesses with complex needs to optimize storage capacity and throughput.

Mabqi

Grant in 2025
Mabqi, headquartered in Grabels, France, is a biopharmaceutical company specializing in immunotherapy. It operates an antibody discovery platform, enabling the identification and development of innovative, proprietary therapeutic molecules.

The QA Company

Series A in 2025
The QA Company specializes in AI-driven knowledge management solutions. It develops a question-and-answer platform that streamlines access to internal information, supporting decision-making and enhancing productivity across diverse industries such as HR, project management, legal, and technical support. The platform enables businesses to create AI chat assistants for their documents and websites.

Keey Aerogel

Series A in 2025
Keey Aerogel is a specialized manufacturer of silica aerogel, utilizing a closed-loop process that recycles construction waste, carbon dioxide, and ethanol. The company focuses on the valorization of silica-containing materials from construction and demolition activities, aiming to create energy-efficient building solutions and materials for various industrial applications. By producing this innovative nanoporous material, Keey Aerogel provides effective thermal insulation in ambient conditions, contributing to sustainability in construction and refurbishment projects.

HEXANA

Grant in 2025
HEXANA develops an energy platform that integrates sodium-cooled fast-neutron reactors with a thermal management system and high-temperature storage to deliver flexible on-demand electricity and process heat while reducing nuclear waste. The modular reactors are designed for both on-site and grid-scale deployment, enabling flexible power production and direct industrial heat applications with emphasis on safety and waste management.

AISPRID

Series A in 2025
AISPRID is a robotic company that manufactures autonomous robots for soft fruit picking.

Coave Therapeutics

Series A in 2025
Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Its platform enables targeted delivery of therapeutic genes to the CNS, enhancing autophagy and lysosomal function, with a focus on improving patient outcomes for conditions like ALS.

NEBULA

Grant in 2024
NEBULA maps 3D macromolecule using dataset-free genAI and physics, enhancing drug target discovery, which forms the basis of all new drugs.

GAiF Ai

Series A in 2024
GAiF Ai is an online community driving Africa's generative AI revolution.

Biomemory

Series A in 2024
Biomemory is a deep-tech company focusing on innovative data storage solutions for large enterprises and institutions. It leverages molecular engineering to create cost-effective, energy-efficient appliances that enable exabyte-scale storage. The company's advanced data storage drives utilize a biobased system that encodes substantial amounts of data on long DNA strands, significantly surpassing the capacity of traditional storage methods such as solid-state drives and magnetic tapes. Biomemory's technology offers remarkable durability, ensuring data stability at ambient temperatures without the need for energetic input or CO2 emissions, making it an environmentally friendly choice. This approach provides researchers and organizations with a long-lasting storage solution, capable of preserving information for thousands of years.

Mirabelle

Grant in 2024
Mirabelle is a technology-driven financial services company focused on addressing the financial needs of retirees. It specializes in offering reverse mortgage loans and life annuities, with a commitment to providing secure and informed decision-making processes. The company's core business involves advising on life annuity financing, ensuring retirees have access to guaranteed monthly income supplements, and assisting with senior housing renovations. Mirabelle's mission is to enable retirees and their families to live comfortably and securely in their homes during their golden years.

Lingua Custodia

Grant in 2024
Founded in 2011, Lingua Custodia specializes in developing SaaS-based software for machine translation tailored to the financial domain. Its flagship product, VERTO, offers customized translation solutions for finance professionals, serving financial institutions, language service providers, and other finance-related entities.

Hub2.Io

Series A in 2024
Hub2.Io is a system for digitizing ongoing transactions. Services like cash out, to pay, manage, and others are offered by them. Connecting businesses to their infrastructure will enable them to accept and process payments quickly and safely.

Meiogenix

Series A in 2024
Meiogenix is a biotechnology company developing breeding technologies to uncover unexplored genetic diversity in organisms, expanding natural biodiversity and enabling the development of products to address global food, climate, sustainability, and industrial challenges. It uses chromosome-editing-based approaches to modulate the frequency of homologous recombination in eukaryotic cells, enabling natural breeding and delivering new products for farmers and industry.

Faircraft

Series A in 2024
Faircraft develops a lab‑grown alternative to animal leather using synthetic biology, material science, and tissue engineering. The company produces a cell‑based material that offers the same mechanical strength and durability as premium leather while eliminating animal slaughter. By culturing cells in controlled environments, Faircraft reduces carbon dioxide emissions and provides a sustainable, cruelty‑free option for the fashion and upholstery industries.

Interactive Autonomous DYnamic Systems

Grant in 2024
Iadys designs, develops, and delivers robotic and AI innovations aimed at environmental preservation. The company's flagship product, the Jellyfishbot, is a robot that collects floating waste and oil in water bodies and performs underwater measurements. Iadys also offers the Mobile Oil Skimmer, which is used for oil spill response. These products are designed to access and clean hard-to-reach areas, contributing to cleaner and safer aquatic environments.

Fudzs

Grant in 2024
Fudzs specializes in sustainable bioeconomy, developing eco-friendly cell bioproduction processes using cutting-edge bioreactor technology. By integrating advanced biomaterial engineering with cellular science, Fudzs enables mass production of cells at reduced costs, opening new market opportunities.

Beyond Aero

Series A in 2024
Hangarar is an aeronautical services platform based in Brazil that focuses on enhancing general aviation. The company aims to transform the market by providing timely and secure information to pilots, ensuring they have access to organized data whenever needed. By streamlining the booking process through a mobile platform, Hangarar simplifies the logistics of finding and securing aviation services at various destinations, allowing pilots to concentrate on flying.

Beyond Aero

Series A in 2024
Beyond Aero designs and develops hydrogen-electric propulsion systems for business aviation, aiming to redefine private travel with zero-emission, six-passenger aircraft. The company is redesigning a CS23 airframe around hydrogen fuel-cell propulsion and an electric drive, integrating hydrogen storage, fuel cells, and advanced cooling to enable flights up to 800 nautical miles (approximately 1,500 km). Founded in 2020, it operates from offices in Toulouse, Paris, and Los Angeles and relies on a multinational engineering team. The business model centers on delivering energy-efficient private aviation powered by hydrogen-electric technology, seeking to reduce environmental impact compared with traditional jets. Beyond Aero has demonstrated progress with a manned hydrogen-electric flight in France and participates in industry initiatives advancing zero-emission aviation.

Okomera

Grant in 2024
Okomera is a biotech start-up focused on enhancing access to more effective, precision-based cancer therapies. The company has pioneered the automation and miniaturization of individualized tumor biopsy research, developing advanced medical technologies that leverage microfluidic 3D cellular assays. These innovative technologies enable the prediction of patient-specific responses to cancer treatments by automating relevant biopsy testing. In this process, tumor cells are cultivated within thousands of microfluidic droplets and exposed to numerous conditions simultaneously. This approach allows healthcare providers to expedite the development and delivery of modern cancer therapies, ultimately improving treatment outcomes for patients.

Kriptown

Series A in 2024
Kriptown is a platform facilitating equity financing for regional startups and small-to-medium enterprises (SMEs). It uses advanced technology and innovative strategies, allowing members to participate by contributing digital assets. These assets can later be stored, used, or traded on Kriptown's secondary market.

VELA

Series A in 2024
VELA is an innovative 100% wind-powered maritime transport. It has been working to address the climate emergency by providing a creative, sustainable, and socially responsible maritime transportation solution.

Inbolt

Series A in 2024
Inbolt is a company focused on enhancing industrial operations through advanced vision systems for robots. It has developed a vision-based artificial intelligence that enables real-time decision-making in various environments, allowing for smarter automation of complex tasks. The company's technology includes a tool positioning system that provides real-time quality control for manual operations such as torquing, drilling, and riveting. By implementing these innovations, Inbolt aims to reduce errors in operations and improve overall quality control, thereby streamlining industrial processes and increasing efficiency.

Patrowl

Series A in 2024
Patrowl is a pioneering cybersecurity solution that automates vulnerability detection and remediation. It employs AI and expert knowledge for real-time asset identification and vulnerability assessment across wide areas. The platform offers an intuitive dashboard to visualize security levels, provides tailored remediation solutions, and facilitates tracking of remediation progress.

Hepta Medical

Series A in 2024
Hepta Medical develops a microwave ablation platform designed for minimally invasive, nonsurgical treatment of early lung cancer. Its proprietary technology features an ablation catheter with integrated temperature sensing, enabling real-time monitoring and control of tissue ablation size.

Enalees

Series A in 2024
Enalees develops molecular diagnostic tests for animals that can be used directly by veterinarians, enabling rapid on-site detection of infectious diseases in pets and livestock. The company provides fast, easy-to-use diagnostic kits with integrated reagents and a portable reader, designed for use in clinics and field settings to support timely and accurate treatment decisions.

Aura Aero

Grant in 2024
Aura Aero designs and manufactures aircraft with a focus on accelerating air transport decarbonization.

Yumgo

Series A in 2024
Yumgo is a plant-based egg startup that develops white and yellow egg substitutes for baking and cooking. The products are made from vegetable proteins with natural ingredients and are free from allergens, enabling professional chefs and food manufacturers to create sustainable and inclusive culinary creations without compromising taste or texture.

Ray studios

Series A in 2024
Ray Studios is a Tattoo removal studio that employs hydraulic acoustic wave technology in its "Le Ray Spark" Tattoo removal treatment device.

GenoMines

Grant in 2024
GenoMines is a company focused on sustainable mining through innovative biological methods. It specializes in using plant-based technologies to extract critical metals from soils that are below traditional cut-off grades. By genetically enhancing hyperaccumulator plants, GenoMines leverages nature's ability to absorb metals, thereby not only sustainably mining these resources but also depolluting soils and increasing the availability of agricultural sites. This approach addresses significant environmental and societal challenges associated with conventional mining methods, aiming to support the transition to green energy in a responsible manner.

Continuity

Series A in 2024
Continuity offers a software-as-a-service (SaaS) platform that utilizes artificial intelligence and open data to identify outdated or invalid insurance contracts. The platform operates across four key product lines: Professional Indemnity, Commercial Property, Construction Workers Insurance, and Directors & Officers Liability. By analyzing data consistently and at scale, Continuity provides insurers with a comprehensive view of small and medium-sized enterprises (SMEs), ensuring that each business is adequately covered throughout its lifecycle. This innovative approach helps to enhance the accuracy and reliability of insurance coverage for SMEs.

LAfricaMobile

Series A in 2024
Founded in 2014, LAfricaMobile operates as a digital multichannel cloud communication platform based in Dakar, Senegal. It facilitates interactions between businesses and Africans on the continent and in the diaspora through customized solutions tailored to Africa's unique context.

Biodol Therapeutics

Grant in 2024
Biodol Therapeutics develops first-in-class therapies for chronic pain by targeting the FLT3 receptor, a receptor tyrosine kinase expressed on sensory neurons that triggers and sustains neuropathic pain. The company advances extracellular inhibitors of FLT3 to block ligand binding and disrupt pain signaling, with goals to reduce allodynia, hypersensitivity and spontaneous pain while preserving normal nervous system function. By pairing FLT3 inhibition with opioid analgesia, Biodol Therapeutics aims to enhance pain relief and potentially lower opioid-related safety risks. Founded in 2015 and based in Clapiers, France, the company collaborates with academic researchers to validate FLT3 as a therapeutic target for chronic pain.

Eyco

Series A in 2024
Eyco is a manufacturer specializing in the design and production of smart circuits and hardware elements for the digital applications sector. Operating within the European microelectronics industry, the company focuses on creating innovative industrial machinery that minimizes environmental impact. By ensuring efficient mass production tailored to client specifications, Eyco enables secure digital applications while promoting sustainability in technology. Its commitment to advancing the high-tech ecosystem of electronics positions Eyco as a key player in the development of environmentally responsible solutions in the digital landscape.

Hephaistos Pharma

Grant in 2024
Hephaistos Pharma is a biotechnology company developing an immunotherapy platform aimed at producing advanced oncology treatments. Its platform enhances commercialized antibodies by stimulating the immune system, turning 'cold' tumors into targets for immune response.

Magnetfab

Grant in 2024
Magnetfab manufactures micromagnets for microelectronic applications using thin-film sputtering to produce rare-earth magnets with micron-level precision and wafer-scale fabrication. This enables integration of compact magnetic components into advanced electronic systems across consumer electronics, robotics, and quantum computing, prioritizing reliability and scalability.

Touch Sensity

Grant in 2024
Touch Sensity is an information technology company focused on the development of sensitivity technology that enhances the interaction between objects and their environments. It specializes in Internet of Things (IoT) applications and advanced sensor technology, creating solutions that are adaptable to various sizes, shapes, and surface topologies. The company's innovative approach is sensorless and non-invasive, allowing for the comprehensive capture of data related to pressure, extension, and deformation across complete surfaces. This capability enables clients to gather and analyze detailed information about physical interactions, thereby enhancing the functionality and responsiveness of their products and systems.

Ascendance

Funding Round in 2024
Founded in 2018 by four ex-Airbus engineers: Jean-Christophe Lambert, Thibault Baldivia, Clément Dinel and Benoît Ferran, Ascendance is an industrial start-up with a mission to decarbonise aviation. Based in the heart of Toulouse, the European capital of aviation, it has developed and markets two products: an innovative hybrid-electric propulsion system ‘Sterna’, and a hybrid-electic vertical take-off and landing (VTOL) aircraft powered by Sterna technology, ‘Atea’.

Tribun Health

Grant in 2024
Tribun Health specializes in digital health solutions for cancer detection. It develops innovative systems that enable diagnostic laboratories and pharmaceutical/biotech companies to manage, analyze, and share cellular images efficiently.

SeaBeLife

Grant in 2024
SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Chipiron

Grant in 2024
Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.

Surge

Grant in 2024
Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.

Alice & Bob

Grant in 2024
Alice & Bob is a Paris-based quantum computing hardware company founded in 2020. It develops universal quantum computers designed to enable industries and researchers to tackle complex problems. The company focuses on integrating error correction into its hardware, using cat qubits with built-in error resilience, and provides a platform with cloud access for remote testing and expert support. This combination aims to deliver early quantum computational advantages for practical applications in science and industry.

Sequans Communications

Grant in 2024
Sequans Communications designs and supplies cellular semiconductor solutions for broadband Internet of Things markets, offering 5G and 4G chips and modules for massive, broadband, and critical IoT applications. Its product platforms include Monarch LTE-M/NB-IoT and Calliope Cat 1 for low-power, integrated IoT deployments, Cassiopeia Cat 4/Cat 6 for 4G and 5G, and Taurus for residential, enterprise, and industrial use. Founded in 2003 and headquartered in Paris, the company operates globally with offices in the United States, United Kingdom, Israel, Hong Kong, Singapore, Taiwan, South Korea, and China. Its customer base spans smart mobility and logistics, smart utility meters, smart cities and industries, e-health, and smart homes, reflecting a focus on cellular semiconductor solutions for a range of IoT connectivity needs.

ABIONYX Pharma

Grant in 2024
ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Sunver

Grant in 2024
Sunver is a start-up offering the first fully plug & play B2B SaaS solution for tourism establishments and restaurants, enabling them to create and configure a Guest App in just a few minutes.

HawkCell

Series A in 2024
HawkCell specializes in advanced magnetic resonance imaging (MRI) solutions for veterinary clinics and preclinical research labs. Utilizing non-ionizing, three-dimensional MRI technology adapted for diverse animal morphologies, the company offers sustainable systems enhanced by artificial intelligence algorithms to provide precise and insightful animal healthcare services.

UniFox

Grant in 2024
UniFox is an AI-powered ecosystem focused on sustainable investment, integrating green energy and eco-responsible technologies into its offerings for both individual and institutional investors. The company operates through four divisions: B2C, B2B, Capital Ventures, and Green DeFi. Its flagship product, VulpesAI, is a multi-modal AI engine that analyzes market data, sentiment, and environmental, social, and governance (ESG) factors to create optimized investment strategies. VulpesAI is designed to be environmentally friendly, utilizing renewable energy sources and low-frequency micro-servers to minimize its carbon footprint. The B2C segment provides AI-driven portfolio management, enabling users to access comprehensive market insights and tailor investment strategies based on AI-generated signals. In the B2B sector, UniFox delivers institutional solutions through REST API access to advanced data and metrics for large-scale investments and green projects. Its Green DeFi division finances sustainable technology initiatives, utilizing decentralized finance methods, eco-taxed products, and tokens to support environmentally friendly ventures. UniFox's mission is to democratize investment, making it more accessible and aligned with ecological values while addressing common trading challenges faced by novice investors.

Groover

Series A in 2024
Groover is an innovative platform designed specifically for independent artists, focusing on music promotion and discovery. It has cultivated a community of 200,000 artists across more than 186 countries. The platform allows musicians to directly submit their music to media outlets, radio stations, playlists, and record labels, ensuring they receive valuable feedback from a vetted network of 3,000 music curators and professionals. With over two million feedback interactions on tracks, Groover provides artists with the opportunity to obtain honest insights and tangible sharing proposals, facilitating their growth and visibility in the competitive music industry.

Agrilife Studio

Series A in 2024
Agrilife Studio operates a startup studio focused on enhancing agricultural efficiency and productivity through technology. It offers tools such as data analytics, precision agriculture resources, and market access platforms, empowering farmers to make informed decisions about their crops and livestock while facilitating connections with buyers.

Greenerwave

Series A in 2024
Greenerwave develops electromagnetic wave control technology to address mobility and connectivity challenges. Its electronically reconfigurable surfaces act as electromagnetic mirrors to control frequencies, enabling clients to design high performance, cost-effective applications and improve indoor wireless connectivity.

Panopli

Series A in 2024
Panopli is a customization service based in Saint-Ouen, France, established in 2017. The company operates an online marketplace that specializes in personalized gifts, including artistic clothing, decorative items, and various gift solutions such as art pieces, t-shirts, sweaters, shorts, and posters. Panopli's platform simplifies the gifting process by allowing users to browse and select items, which are then directly shipped to the recipient. This service aims to make gift-giving more accessible and convenient, ensuring that customers can find and send artistic goods without the hassle of managing orders and deliveries themselves.

AQEMIA

Series A in 2024
AQEMIA is a pharmaceutical technology company specializing in drug discovery. It employs a proprietary platform that integrates quantum-inspired physics with machine learning algorithms to accelerate and enhance the identification of new drug candidates tailored to specific therapeutic targets. This innovative approach enables AQEMIA to generate a robust pipeline of novel drug leads, aiming to improve efficiency and accuracy in predicting the affinity between drug candidates and their intended targets.

Aldoria

Series A in 2024
Aldoria specializes in space situational awareness services. It collects, processes, and uses data on space debris, satellites, and derelicts to monitor potential hazards and enable operators to adjust orbital routes, ensuring safety and sustainability in space.

Temo

Series A in 2024
Temo is a manufacturer of portable electric motors designed for small watercraft, including dinghies, sailing boats, and rowboats. The company focuses on creating lightweight and easy-to-install outboard electric propulsion systems that enhance the user experience on the water. By providing innovative and accessible solutions, Temo aims to improve the functionality and enjoyment of various types of small craft.

I.Ceram

Grant in 2024
I.Ceram SA is a France-based company that specializes in the design, manufacture, and marketing of alumina bio-ceramic implants for various joints of the human body. Founded in 2005 and headquartered in Limoges, I.Ceram offers a range of implants for the ankle, knee, hip, spine, shoulder, wrist, skull, tibia, and foot, as well as osteosynthesis products. The company operates both domestically and internationally, emphasizing innovation and high-quality materials in its product offerings. I.Ceram is a subsidiary of Investissement Développement.

Neocem

Venture Round in 2024
Neocem is a manufacturer that specializes in producing low-carbon cements for the construction industry. The company focuses on creating innovative binding materials derived from calcined flash clays, which are designed to reduce the carbon footprint associated with traditional cement production. Neocem utilizes a novel procedure that allows for the incorporation of raw materials sourced from recovery sectors, thereby promoting sustainability in building practices. Through its commitment to environmentally friendly solutions, Neocem aims to contribute to a greener future in construction.

Novacium

Grant in 2023
Novacium operates as an innovative start-up that specializes in the next generation material development.

Okomera

Grant in 2023
Okomera is a biotech start-up focused on enhancing access to more effective, precision-based cancer therapies. The company has pioneered the automation and miniaturization of individualized tumor biopsy research, developing advanced medical technologies that leverage microfluidic 3D cellular assays. These innovative technologies enable the prediction of patient-specific responses to cancer treatments by automating relevant biopsy testing. In this process, tumor cells are cultivated within thousands of microfluidic droplets and exposed to numerous conditions simultaneously. This approach allows healthcare providers to expedite the development and delivery of modern cancer therapies, ultimately improving treatment outcomes for patients.

HUVY

Grant in 2023
HUVY employs artificial intelligence to optimize dermatological treatment pathways and deliver critical medical information in real-time.

eyeGauge

Grant in 2023
EyeGauge is a Paris-based Deep Tech company focused on the maritime industry. It aims to accelerate decarbonization by automating data collection from ships' systems, enabling consistent, comprehensive emission tracking and analysis. This helps shipowners optimize operations and comply with regulations like EEXI and CII.

Prove & Run

Series A in 2023
Prove & Run has been created with the idea that large scale deployment of connected objects will become a target for remote cyber-attacks and that the technologies in use in the mobile industry were insufficient to answer to the challenge. When designing connected objects, security engineers can in effect rely on three pillars: (1) Secure elements or hardware coprocessors; (2) Trusted Execution Environment (TEE) or secure OSs; (3) Hardware - or software-based hypervisors. In order to resist to sophisticated remote attacks, the last two need to be formally proven so as to be as close as possible to zero-bugs. This is what we have done at Prove & Run with ProvenCore, a formally proven secure OS and ProvenVisor a next generation secure hypervisor. In most cases using of single instance of ProvenCore on a given connected object will be sufficient to protect against hackers with multi-million dollar budgets.

Astraveus

Grant in 2023
Astraveus is developing the Lakhesys platform, an end-to-end cell foundry for cell and gene therapy manufacturing. The platform uses deep process optimization and single-use microfluidic bioprocessors to produce autologous therapies with reduced inputs and infrastructure needs, lowering costs and logistical barriers. By enabling automated, patient-specific biomanufacturing, Astraveus aims to improve access to transformative CGTs. The system builds equipment tailored for each patient to use autologous cells, leveraging microfluidic chip technology to convert cells into therapeutic agents. The approach seeks to scale production of cell and gene therapies while minimizing environmental impact and resource use, supporting more sustainable manufacturing at lower cost.

Poppins

Venture Round in 2023
Poppins is a developer of digital therapeutic technology aimed at enhancing cognitive function in children with learning disorders. The company creates interactive musical games that integrate neurologic music therapy methods to address conditions such as dyslexia, dysphasia, and dyspraxia. These games focus on improving essential skills like concentration, motor skills, and memory through engaging activities that can be performed at home. By leveraging data science and advanced technologies, Poppins interprets learning, language, and motor performance to generate a cognitive score, facilitating personalized treatment plans. The company's mission is to provide accessible digital solutions for children facing learning challenges, ultimately aiming to improve their reading abilities and memory retention while supporting speech therapy.

Injectpower

Grant in 2023
Injectpower specializes in developing energy storage technologies and micro-batteries tailored for medical implants. Their core product is a small, solid-state battery that powers implantable devices, enabling them to function as sensors or actuators for extended periods without the need for recharging. With over 16 years of research and 40 patents, Injectpower's batteries are manufactured using a proven semiconductor supply chain, ensuring high reliability. The company's innovative solutions include batteries for devices that monitor intraocular pressure in glaucoma patients and intracranial pressure and fluid flow, allowing physicians to remotely monitor and diagnose conditions more effectively.

Hughy

Grant in 2023
F&B advertising webapp

Albert

Venture Round in 2023
Albert is a software company that provides a SaaS platform. The company was founded in 2018 and is based in Paris, France.

Spark Cleantech

Grant in 2023
Spark Cleantech is a pioneering company developing a plasma technology to convert greenhouse gases into hydrogen fuel. Their proprietary process, called plasmolysis, uses cold pulsed plasma discharges to convert methane or carbon dioxide and methane mixtures into valuable products such as hydrogen, solid carbon, and carbon monoxide. This technology enables the production of competitive, on-site hydrogen, serving as a direct substitute for fossil fuels in decarbonizing industrial heat and powering the transport industry with carbon-neutral hydrogen fuel.

Mecaware

Series A in 2023
Mecaware specializes in battery recycling services, focusing on recovering critical metals and rare earth elements. Utilizing a patented dynamic combinatorial chemistry process, the company operates in a closed-loop manner with minimal energy requirements and no effluent waste, enhancing resource efficiency and reducing environmental impact for various industries.

Global Bioenergies

Grant in 2023
Global Bioenergies SA specializes in developing a biological process that converts renewable resources into isobutene, a crucial petrochemical building block used in fuels, plastics, organic glass, and elastomers. The company, based in Evry, France, is notable for being one of the few globally and the only one in Europe focusing on this innovative fermentation technology. It operates an industrial pilot plant and is nearing the completion of a demonstration plant in Germany, alongside preparing for its first full-scale production facility in collaboration with Cristal Union, known as IBN-One. In addition to isobutene, Global Bioenergies has expanded its capabilities to include the production of propylene and butadiene, both vital components in the petrochemical sector. The company was founded in 2008 and continues to enhance the efficiency of its processes while offering engineering services related to gas fermentation.

Niryo

Series A in 2023
Niryo is a manufacturer of educational robots designed to facilitate prototype industrial case studies. The company specializes in open-source six-axis collaborative robots that serve as tools for learning robotics and computer programming. By providing these resources, Niryo aims to support educational institutions in delivering higher education and professional training, thereby enhancing the skills of students and professionals in the field of robotics.

Circul'Egg

Grant in 2023
Circul'Egg transforms recycled eggshells into calcium carbonate powder and shell membrane powder for use in animal feed, nutraceuticals, and cosmetics. It promotes sustainable practices by repurposing industrial co-products.

Umiami

Series A in 2023
Founded in Paris in 2020, Umiami is a French food-tech company dedicated to developing plant-based food technology. It specializes in creating whole-cut alternatives that replicate the taste, texture, and smell of meat, aiming to reduce global meat consumption.

Remixt

Grant in 2023
Remixt is a leading Diversity, Equity and Inclusion tech platform dedicated to preventing key HR risks caused by harassment and discrimination. The company is headquartered in Paris, France, with employees in Paris, San Francisco, Toulouse and Annecy. Remixt’s clients include global corporations Heineken, Société Générale, Accenture, Groupe BPCE-Natixis and Hexagon. For more information: http://www.remixt.co

Eramet

Grant in 2023
Eramet is a global leader in alloy metals such as manganese and nickel, focusing on high-end metallurgy. The company also explores growth opportunities in mineral sands like titanium dioxide and zircon, lithium, and recycling sectors.

Toopi Organics

Grant in 2023
Toopi Organics is a biotechnology company based in Langon, France, established in 2019. It develops microbiological and agricultural technologies to transform human urine into fertilizers and biostimulants for agriculture. The company collects and upcycles human urine, depollutes and enriches it with microorganisms to provide natural, economical, and efficient alternatives to chemical fertilizers. Its products include Arbop and Vitip, which support plant growth and crop health, offering farming communities an environmentally conscious option for nutrient supply.

Teale

Series A in 2023
Teale is a prominent digital mental health platform that integrates psychology and technology to facilitate mental health care for individuals and organizations. The company offers personalized and engaging digital healthcare solutions, emphasizing the importance of subconscious well-being. Teale's approach includes individual support and collective workshops tailored to the specific needs of users, thereby enhancing the effectiveness of mental health initiatives. Through its curated network of mental health experts, Teale enables employees to assess their mental health status and access customized digital programs designed to promote their psychological resilience.

Dattak

Series A in 2023
Dattak is a provider of cyber insurance solutions that leverages advanced cybersecurity technologies to enhance risk management for businesses. The company focuses on facilitating insurance brokers in delivering effective resolutions to their clients, particularly targeting small and medium-sized enterprises as well as veterinary specialists and emergency services. By utilizing innovative cybersecurity tools, Dattak assesses the cybersecurity posture of organizations without the need for complicated questionnaires. This approach not only streamlines the insurance process but also equips policyholders with essential tools to prevent and defend against cyberattacks, ultimately helping to reduce overall risk and enhance security in an increasingly digital landscape.

Phagos

Grant in 2023
Phagos develops personalized bacteriophage solutions as a sustainable alternative to antibiotics.

Mob-Energy

Series A in 2023
Mob-Energy is a privately held company founded in 2018 and headquartered in Villeurbanne, Auvergne-Rhône-Alpes. It specializes in the development of innovative charging solutions for electric vehicles. The company designs autonomous charging robots that utilize second-life batteries installed at car parks. These robots can store energy and autonomously move to vehicles that require charging, allowing for a convenient and efficient refueling process. By optimizing existing infrastructure, Mob-Energy aims to enhance the charging experience for electric vehicle owners.

Aviwell

Grant in 2023
Aviwell is a company focused on enhancing animal health and growth through the development of natural and sustainable solutions. Utilizing a microbiota-based platform powered by artificial intelligence and machine learning, Aviwell operates at the intersection of digital and life sciences. The company aims to provide insights that improve animal health and performance while addressing the agri-food industry's challenges in sustainably feeding a growing global population. By prioritizing health and sustainability, Aviwell seeks to offer effective solutions at a reduced cost, ultimately contributing to better nourishment for the planet.

SFE PROCESS

Series A in 2023
SFE Process specializes in the design and manufacture of laboratory equipment, particularly focusing on extraction machines that utilize supercritical fluids. The company develops innovative and modular pressure equipment, providing tailored laboratory systems that cater to a variety of applications. By offering flexible and multipurpose extraction systems, SFE Process enables its clients to efficiently achieve their objectives in diverse research and industrial settings.

Santexpat.fr

Series A in 2023
Santexpat.fr operates as a health insurance platform for French expatriates in more than 200 countries. It helps users compare more than 100 health insurance solutions and subscribe directly to chosen plans through the platform. The service includes teleconsultations with French-speaking doctors around the clock and presents insurer pricing aligned with public rates with no additional fees to the insured. Founded in 2020, the company is based in Paris and serves individuals and businesses living abroad by facilitating access to suitable health coverage.

Cleyrop

Series A in 2023
Cleyrop provides a comprehensive data management solution. It offers a collaborative workspace with features including secure access control, scalable infrastructure management, deployment of data pipelines, visualization tools for data stories, and centralized data asset accessibility.

Santé Académie

Series A in 2023
Santé Académie is an innovative online training platform dedicated to enhancing the skills of healthcare professionals. Recognizing the evolving roles of caregivers and the rapid pace of medical knowledge advancement, the company offers high-quality educational videos accessible via web or mobile. Each course is structured into brief episodes lasting 5 to 15 minutes, catering to the busy schedules of doctors, nurses, pharmacists, and care assistants. The curriculum covers essential clinical and regulatory subjects relevant to daily practice, ensuring that participants receive up-to-date information. The courses are certified by the ANDPC and produced by leading experts from esteemed institutions. With a focus on continuous education and engagement, Santé Académie aims to improve patient care throughout the healthcare continuum, a mission supported by over 20,000 professionals and health institutions, including notable organizations such as GHU Paris psychiatrie & neurosciences and Service de Santé des Armées.

Deemea

Grant in 2023
Deemea develops an AI-driven platform for clinical research, streamlining imaging data management. Its integrated copilot ensures efficiency and reliability in data processing.

EyeLights

Series A in 2023
EyeLights is a developer of innovative motorcycle accessories focused on enhancing rider safety and experience through advanced technology. The company offers a head-up display GPS that projects crucial navigational and safety information directly into the rider's field of vision, allowing them to maintain focus on the road. This universal accessory alerts motorcyclists to potential hazards, such as sharp bends, traffic signals, and speed limits. Designed for easy installation in under five minutes, EyeLights is compatible with various helmet types, including full-face, convertible, and jet helmets. Its compact optical technology enables visibility of GPS data from over two meters away and features audio functionality for extended use of more than eight hours. The device is built to withstand adverse weather conditions, including rain and fog, while remaining lightweight at less than 100 grams. Overall, EyeLights aims to significantly enhance the safety and enjoyment of motorcycle riding.

Pricemoov

Series A in 2023
Founded in Paris, France in 2016, Pricemoov operates an online platform that analyzes sale history and current bookings to provide insights into customer demand. Its cloud-native solution leverages data science and end-to-end automation to help B2B and B2C businesses optimize pricing strategies, adapt to market dynamics, and unlock revenue potential.

Kiro

Series A in 2023
Kiro develops an AI-powered digital health platform that enhances the relevance of lab test results for healthcare professionals and patients. Its tool provides personalized, understandable interpretations of medical biology reports using artificial intelligence to aid clinical decision-making, engage patients, and improve healthcare outcomes.

XXII

Series A in 2023
XXII is a technology company that specializes in video stream analysis through its SaaS platform, XXIICORE. With a team of over 50 employees, the company focuses on designing, developing, and marketing solutions that enable clients to deploy and configure algorithms for effective video analysis. The platform is utilized across various sectors and by local authorities, allowing organizations to measure the benefits of video analysis in real-time. By facilitating the creation of new tools and applications for their algorithms, XXII helps clients enhance operational performance and optimize their use of video data.

GenoMines

Grant in 2023
GenoMines is a company focused on sustainable mining through innovative biological methods. It specializes in using plant-based technologies to extract critical metals from soils that are below traditional cut-off grades. By genetically enhancing hyperaccumulator plants, GenoMines leverages nature's ability to absorb metals, thereby not only sustainably mining these resources but also depolluting soils and increasing the availability of agricultural sites. This approach addresses significant environmental and societal challenges associated with conventional mining methods, aiming to support the transition to green energy in a responsible manner.

Kovalee

Series A in 2023
Kovalee is a mobile app publisher that supports app creators by providing a comprehensive application publishing platform. The company partners with app owners to elevate their apps in the marketplace, offering services such as product enhancement, user acquisition, monetization, and app store optimization. Kovalee's platform features modular design and application testing, enabling developers to focus on content and code while leveraging data-driven strategies. Additionally, the company employs artificial intelligence to predict customer behavior, helping developers optimize their apps for better performance and profitability.

AlgoTherapeutix

Grant in 2023
AlgoTherapeutix develops topical treatments for complex pain conditions, focusing on chemotherapy-induced peripheral neuropathy and diabetic neuropathic pain. The company repurposes existing drugs to target damaged nerve fibers in the skin, avoiding systemic side effects of oral drugs.

PILI

Series A in 2023
Founded in Paris, France in 2012, PILI Inc. specializes in the research and manufacture of bio-fabricated colors using microorganisms. The company designs enzymes and fermentation biotechnologies to efficiently transform sugar into renewable and long-lasting dyes and pigments.

Oneleaf

Grant in 2023
Oneleaf is a startup dedicated to making hypnosis more accessible through its innovative app, which assists users in engaging with self-hypnosis techniques. The platform offers a variety of guided programs aimed at addressing wellness issues such as depression, anxiety, smoking cessation, and weight loss. By leveraging expert guidance in a digital format, Oneleaf enables individuals to tackle harmful habits and enhance their overall well-being. The company aims to empower a billion people to realize their potential through self-hypnosis, promoting personal growth and healthier lifestyles.

NFL Biosciences

Grant in 2023
NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in research and development of medicines that utilize both botanical and pharmaceutical agents to aid individuals attempting to quit smoking. Its primary product, NFL-101, is a clinically developed botanical drug designed specifically to target smoking addiction. This innovative treatment contains minimal amounts of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a unique approach to support smokers in overcoming their addiction.

Miraxess

Venture Round in 2023
Miraxess is a French technology company that develops a plug‑in device called the Mirabook, which extends a smartphone into a full‑featured laptop. The device connects to the phone, providing a larger display, keyboard, and mouse input, thereby enabling users to perform work and entertainment tasks with greater productivity and comfort. By converting mobile phones into portable computing platforms, Miraxess offers a mobile convergence solution that addresses the growing reliance on smartphones for daily digital needs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.